Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gu-Sui-Bu is a traditional Chinese medicine (TCM) derived from the rhizome of *Davallia divaricata* (or *Drynaria fortunei*). It is being investigated by the National Taiwan University Hospital for its therapeutic potential in treating postmenopausal osteoporosis. Traditionally used to promote bone healing and treat fractures, Gu-Sui-Bu is thought to exert its effects by stimulating osteoblast proliferation and differentiation while inhibiting osteoclast activity. These pharmacological actions are largely attributed to its flavonoid content, particularly naringin, which may act as a phytoestrogen or modulate bone morphogenetic protein (BMP) signaling pathways to enhance bone mineral density.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gu-Sui-Bu.